| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes
|
Madanat, Yazan F
|
|
|
11 |
9 |
p. e630-e631
|
artikel
|
| 2 |
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
|
Herrera, Alex F
|
|
|
11 |
9 |
p. e671-e681
|
artikel
|
| 3 |
Environmental impact of haematology care—measurement and mitigation
|
Thomas, Stephen
|
|
|
11 |
9 |
p. e644-e645
|
artikel
|
| 4 |
Etoposide addition and brentuximab vedotin consolidation in first-line treatment of CD30-positive peripheral T-cell lymphoma: can we improve BV–CHP?
|
Julia, Edith
|
|
|
11 |
9 |
p. e634-e636
|
artikel
|
| 5 |
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
|
Díez-Campelo, María
|
|
|
11 |
9 |
p. e659-e670
|
artikel
|
| 6 |
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
|
Della Porta, Matteo Giovanni
|
|
|
11 |
9 |
p. e646-e658
|
artikel
|
| 7 |
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
|
van de Donk, Niels W C J
|
|
|
11 |
9 |
p. e693-e707
|
artikel
|
| 8 |
New insights into pregnancy after stem-cell transplantation
|
The Lancet Haematology,
|
|
|
11 |
9 |
p. e629
|
artikel
|
| 9 |
Oncology service priorities for the new UK Government
|
The Lancet Haematology,
|
|
|
11 |
9 |
p. e629
|
artikel
|
| 10 |
Overcoming the unmet need of Richter transformation: the use of pirtobrutinib
|
Tadmor, Tamar
|
|
|
11 |
9 |
p. e636-e637
|
artikel
|
| 11 |
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
|
Wierda, William G
|
|
|
11 |
9 |
p. e682-e692
|
artikel
|
| 12 |
Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List
|
Pierce, Glenn F
|
|
|
11 |
9 |
p. e638-e640
|
artikel
|
| 13 |
Second allogeneic stem-cell transplantation or donor lymphocyte infusion in patients who relapse after transplantation?
|
Robin, Marie
|
|
|
11 |
9 |
p. e642-e643
|
artikel
|
| 14 |
SintraREViewed: practice changing, or validation required?
|
Buckstein, Rena
|
|
|
11 |
9 |
p. e632-e634
|
artikel
|
| 15 |
Urgent need: evidence-based use of donor lymphocyte infusions
|
Boelens, Jaap Jan
|
|
|
11 |
9 |
p. e641
|
artikel
|
| 16 |
Zanubrutinib-associated ecchymotic lesions
|
Belkaïd, Samy
|
|
|
11 |
9 |
p. e708
|
artikel
|
Tijdschrift beschrijving